0001387131-22-002106.txt : 20220217
0001387131-22-002106.hdr.sgml : 20220217
20220217171820
ACCESSION NUMBER: 0001387131-22-002106
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220215
FILED AS OF DATE: 20220217
DATE AS OF CHANGE: 20220217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MORRIS JESSICA EDGAR
CENTRAL INDEX KEY: 0001656531
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36019
FILM NUMBER: 22649413
MAIL ADDRESS:
STREET 1: C/O TONIX PHARMACEUTICALS HOLDING CORP
STREET 2: 509 MADISON AVE., SUITE 306
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp.
CENTRAL INDEX KEY: 0001430306
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261434750
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 26 MAIN STREET, SUITE 101
CITY: CHATHAM
STATE: NJ
ZIP: 07928
BUSINESS PHONE: 212-980-9155
MAIL ADDRESS:
STREET 1: 26 MAIN STREET, SUITE 101
CITY: CHATHAM
STATE: NJ
ZIP: 07928
FORMER COMPANY:
FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC.
DATE OF NAME CHANGE: 20080320
4
1
ownership.xml
BENEFICIAL OWNERSHIP
X0306
4
2022-02-15
0
0001430306
Tonix Pharmaceuticals Holding Corp.
TNXP
0001656531
MORRIS JESSICA EDGAR
C/O TONIX PHARMACEUTICALS HOLDING CORP
26 MAIN ST., SUITE 101
CHATHAM
NJ
07928
0
1
0
0
Chief Operating Officer
Stock Option
0.207
2022-02-15
4
A
0
1100000
0.00
A
2023-02-15
2032-02-15
Common Stock
1100000
1100000
D
Stock Option
0.414
2022-02-15
4
A
0
1100000
0.00
A
2023-02-15
2032-02-15
Common Stock
1100000
1100000
D
Stock Option
0.621
2022-02-15
4
A
0
1100000
0.00
A
2023-02-15
2032-02-15
Common Stock
1100000
1100000
D
Stock Option
0.828
2022-02-15
4
A
0
1100000
0.00
A
2023-02-15
2032-02-15
Common Stock
1100000
1100000
D
One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
10% of the option vests on the first anniversary of issuance, 10% on the second anniversary of issuance, 40% on the third anniversary of issuance, and 40% on the fourth anniversary of issuance.
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.
/s/ Jessica Morris
2022-02-17